June 16, 2026. 19 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score.
The DEA placed 3-methoxyphencyclidine, a dissociative anesthetic with no accepted medical use, into Schedule I, impacting any potential research involving this substance and clarifying its legal status separate from cannabis.
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I
The DEA temporarily placed bromazolam, a benzodiazepine sometimes found as an adulterant in cannabis products, into Schedule I, making it illegal and impacting patient safety/clinician awareness.
Read more →The DEA placed five benzodiazepine analogs into Schedule I, impacting their availability and potentially prompting clinicians to reconsider treatment plans involving these substances as alternatives to cannabis for anxiety or insomnia.
Read more →Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA temporarily placed 2-fluorodeschloroketamine into Schedule I, potentially impacting research and clinical use should this substance be considered as an adjunct therapy alongside cannabis for certain conditions.
Read more →Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I
The DEA placed 4-fluoroamphetamine into Schedule I, potentially impacting research access and clinical use should similar scheduling actions occur for cannabinoids or related compounds.
Read more →The DEA placed potent synthetic opioids N-pyrrolidino metonitazene and N-pyrrolidino protonitazene into Schedule I, impacting cannabis clinicians who may encounter patients with co-prescribed medications or polysubstance use disorders.
Read more →The DEA placed two synthetic opioids, N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene, into Schedule I, impacting clinicians needing to differentiate these substances from cannabis when evaluating patient toxicology reports or substance use disorders.
Read more →The DEA placed four synthetic cannabinoids into Schedule I, classifying them as having a high potential for abuse and no accepted medical use, impacting clinical practice and legal considerations regarding cannabinoid products.
Read more →Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I
The DEA temporarily placed bromazolam, a benzodiazepine sometimes found as adulterant in cannabis products, into Schedule I, impacting its legality and clinical use.
Read more →Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
The DEA placed cumyl-pegaclone, a synthetic cannabinoid, into Schedule I, meaning it has a high potential for abuse and no currently accepted medical use in the United States.
Read more →Schedules of Controlled Substances: Placement of 4-Chloromethcathinone in Schedule I
The DEA placed 4-chloromethcathinone, a synthetic cathinone unrelated to cannabis, into Schedule I, impacting clinicians by restricting research and patient access should it be encountered in clinical practice.
Read more →The DEA temporarily scheduled six synthetic opioids as Schedule I controlled substances, impacting clinicians who may encounter these substances in patient toxicology screens or differential diagnoses.
Read more →Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I
The DEA placed synthetic cannabinoid MDMB-4en-PINACA into Schedule I, classifying it as having a high potential for abuse and no accepted medical use, impacting clinical practice and patient access.
Read more →This temporary scheduling action does not directly impact cannabis but clarifies federal control over fentanyl analogs, potentially affecting pain management discussions with patients considering alternatives.
Read more →The DEA temporarily placed N-pyrrolidino metonitazene and N-pyrrolidino protonitazene into Schedule I, impacting clinicians by restricting their use and potentially raising awareness of novel synthetic opioids appearing in the unregulated cannabis market.
Read more →The DEA placed five benzodiazepine analogs into Schedule I, impacting potential clinical considerations for practitioners evaluating patient-reported use of these substances alongside cannabis.
Read more →Exempt Chemical Preparations Under the Controlled Substances Act
A 2023 rule clarifies that hemp-derived extracts containing no more than 0.3% delta-9 THC are exempt from Controlled Substances Act regulation, impacting legal access for some patients and clinicians.
Read more →Schedules of Controlled Substances: Temporary Placement of Seven Benzimidazole-Opioids in Schedule I
The DEA temporarily placed seven synthetic opioids in Schedule I, impacting research and potentially diverting attention/resources from cannabis-based pain management studies.
Read more →Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I Substance
The DEA proposed placing hexahydrocannabinol (HHC), a synthetic cannabinoid not found naturally in cannabis, into Schedule I alongside other controlled substances like marijuana.
Read more →Digest-Level Clinical Commentary
I must note that this digest concerns synthetic drugs and fentanyl analogues rather than cannabis itself, which signals that regulatory agencies are prioritizing enforcement against novel psychoactive substances and opioid derivatives that pose acute overdose risks. As a cannabis medicine practitioner, I observe this regulatory activity reflects broader public health concerns about uncontrolled synthetic drug markets, which creates an important clinical distinction: cannabis remains Schedule I federally despite growing medical evidence, while these synthetic compounds are being rapidly scheduled due to direct harm signals and lack of therapeutic utility. This divergence underscores that evidence-based cannabis medicine must operate within a regulatory landscape shaped primarily by concerns about other drug classes, requiring careful patient counseling about legal status and access limitations that differ significantly from the synthetic substances being controlled.
These regulatory actions reflect the ongoing challenge of controlling novel synthetic drugs that emerge faster than formal scheduling processes can accommodate, with temporary placements indicating expedited responses to imminent public health threats. The predominance of synthetic cannabinoids, benzodiazepines, nitazenes, and fentanyl analogs suggests that clandestine chemists continue to exploit structural variations to circumvent existing controls while maintaining pharmacological potency. Clinicians should remain vigilant for emerging intoxication patterns and withdrawal syndromes from these agents, as their novelty often means limited safety data and unpredictable toxicity profiles in patient populations.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
